Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The companyâs lead product candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy. Source
No articles found.
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology compa...
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a...
We are a clinical stage biopharmaceutical company leveraging our two proprietary t...
We are a clinical stage biopharmaceutical compa...
Omnicell, Inc., is a leading provider of solutions targeting patient safety and op...
Omnicell, Inc., is a leading provider of soluti...
Aptose Biosciences is a clinical-stage biotechnology company developing personaliz...
Aptose Biosciences is a clinical-stage biotechn...
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to ...
Rexahn Pharmaceuticals is a clinical stage biop...
Corcept is a pharmaceutical company engaged in the discovery, development and comm...
Corcept is a pharmaceutical company engaged in ...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
Join the National Investor Network and get the latest information with your interests in mind.